ArticleInternational journal of surgery case reports2026
Coexisting focal nodular hyperplasia and diffuse hepatic metastases from an ileal neuroendocrine tumor: a case report and literature review.
Article in International journal of surgery case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Focal nodular hyperplasia (FNH) is a benign liver lesion usually associated with vascular abnormalities. Neuroendocrine tumors (NETs), on the other hand, frequently metastasize to the liver and typically appear as hypervascular lesions. The coexistence of FNH and diffuse hepatic metastases from an ileal NET is exceptionally rare and represents a major diagnostic challenge because both entities may present as hypervascular liver lesions, potentially leading to misdiagnosis and inappropriate management. Case presentation: A 56-year-old woman with a history of epilepsy treated with sodium valproate presented with progressive right upper quadrant pain and abdominal distension. Imaging showed a large hepatic lesion suggestive of FNH along with multiple hypervascular liver nodules suspicious for metastases. A CT-guided liver biopsy demonstrated metastatic well-differentiated NET with a Ki-67 index below 2%. Laboratory tests revealed elevated chromogranin A and urinary 5-hydroxyindoleacetic acid levels. The patient also had chronic diarrhea and moderate tricuspid regurgitation consistent with carcinoid syndrome. A ^68 Ga-DOTANOC positron emission tomography/computed tomography localized the primary tumor to the ileum. The integration of radiological, functional, and histopathological findings enabled accurate diagnosis and appropriate therapeutic planning. Surgical resection of the primary tumor was performed, followed by long-acting octreotide therapy. The patient remained clinically stable, with no progression of the hepatic lesions during follow-up. Clinical discussion: The presence of multiple hypervascular liver lesions in patients with NETs raises important diagnostic issues, especially when benign and malignant lesions coexist. This case demonstrates the value of integrating hepatobiliary magnetic resonance imaging (MRI), histopathological confirmation, and functional imaging to accurately distinguish FNH from metastatic disease and to guide appropriate therapeutic management. Conclusion: The coexistence of FNH and diffuse liver metastases from an ileal NET is rare. This case highlights the pivotal role of a multimodal diagnostic approach combining hepatobiliary MRI, functional imaging, and targeted histopathological confirmation to distinguish benign from malignant hypervascular liver lesions, avoid diagnostic pitfalls, and optimize patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.